Last update 16 May 2024

Adebrelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
+ [2]
Target
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Inactive Indication-
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationSpecial Review Project (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Extensive stage Small Cell Lung Cancer
CN
28 Feb 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-squamous non-small cell lung cancerPhase 3
CN
15 Mar 2024
Small Cell Lung CancerPhase 3
CN
20 Jan 2021
Non-small cell lung cancer stage IIIPhase 3
CN
14 Jul 2020
Advanced Hepatocellular CarcinomaPhase 2
CN
02 Aug 2022
HER2 Positive Breast CancerPhase 2
CN
23 May 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2--
Hepatocellular CarcinomaPhase 2
CN
-
HER2 mutant non-small cell lung cancerPhase 2--
Advanced Esophageal Squamous Cell CarcinomaDiscovery
CN
01 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
24
(ujxomzoxvv) = kvayxiibbe kbmzgrolum (geglzqhnur )
Positive
02 Jun 2022
Phase 2
39
(dkavckwlgo) = tgovlcoxor qfswlakvon (bptjoouqpu )
Positive
23 Oct 2023
(previously treated with anti-PD-1 antibody)
(dkavckwlgo) = thcccpmzsw qfswlakvon (bptjoouqpu )
Phase 3
28
Adebrelimab + carboplatin + etoposide + thoracic radiotherapy
(czdqlwydbf) = mfihapsnfk svgfowklkf (rppwprgxar )
Positive
20 Mar 2024
Phase 1
41
(karagbwbkw) = bjutxvrqiv jfmqvflfjq (ywvtgcatae )
Positive
10 Sep 2022
Phase 1
23
(qssbyjdhzo) = ahgkwrqizs hashwnnyyy (roplprfcbd )
-
08 Sep 2021
Phase 2
23
liposomal irinotecan+5-fluorouracil+SHR-1316
(vcjzdsbmvc) = gbtmqcrzyk thvpkxnqho (iawddaoqxi, 1.2 - 15.8)
Positive
01 May 2021
Phase 1
-
SHR-1316+chemotherapy
(imsnzzzmip) = llqhbwipku pwcopuhlmj (dzltsjgwbv, 39.5 - 71.1)
Positive
03 Apr 2022
placebo+chemotherapy
-
Phase 3
462
(edlpmhvkun) = ipkuijghir sjyzdpazcx (nzwzqxjbnn, 13.2 - 17.3)
Positive
07 Dec 2023
Placebo
(edlpmhvkun) = norrejajlk sjyzdpazcx (nzwzqxjbnn, 11.3 - 13.9)
Phase 2
63
chemotherapy+sequential chest radiotherapy+SHR-1316
(waevptevar) = irnalkopbb oyewxrflzf (vkdczuokdw, 4.3 - 9.7)
Positive
26 May 2023
Pubmed
ManualManual
Phase 1
37
(arsovvnflh) = emqsahnwrd ideybarqir (mpnkcspuyn, 35.9 - 66.6)
Positive
30 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free